 Connection
Stanley Szefler to Interleukin-13
This is a "connection" page, showing publications Stanley Szefler has written about Interleukin-13.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.327 |
|
|
|
-
Szefler S, Corren J, Silverberg JI, Okragly A, Sun Z, Natalie CR, Zitnik R, Siu K, Blauvelt A. Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II). Immunotherapy. 2024; 16(20-22):1211-1216.
Score: 0.218
-
Corren J, Szefler SJ, Sher E, Korenblat P, Soong W, Hanania NA, Berman G, Brusselle G, Zitnik R, Natalie CR, Sun L, Siu K, Wu WS, Lio P, Armstrong AW. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May; 12(5):1215-1224.e3.
Score: 0.051
-
Spahn JD, Szefler SJ, Surs W, Doherty DE, Nimmagadda SR, Leung DY. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol. 1996 Sep 15; 157(6):2654-9.
Score: 0.031
-
Yang IV, Pedersen BS, Liu A, O'Connor GT, Teach SJ, Kattan M, Misiak RT, Gruchalla R, Steinbach SF, Szefler SJ, Gill MA, Calatroni A, David G, Hennessy CE, Davidson EJ, Zhang W, Gergen P, Togias A, Busse WW, Schwartz DA. DNA methylation and childhood asthma in the inner city. J Allergy Clin Immunol. 2015 Jul; 136(1):69-80.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|